16th Annual Meeting of the Asian Cellular Therapy Organization (ACTO 2025) — Germonizer Bronze Sponsor

The16th Annual Meeting of the Asian Cellular Therapy Organization (ACTO) will be held from 14–16 August 2025 at the Academia within the Singapore General Hospital (SGH) Campus. Hosted in collaboration with the SingHealth Duke‑NUS Cell Therapy Centre, ACTO 2025 convenes clinicians, researchers, regulators and industry stakeholders across Asia to discuss progress, challenges and opportunities in cell and gene therapy.

Key Themes and Focus Areas

ACTO 2025 will focus on scientific and regulatory topics that are central to the advancement of cellular therapies across the region, including:

• Mesenchymal stem cells (MSCs) and their therapeutic applications.
• Exosome‑based therapeutics and translational challenges.
• Regulatory harmonisation and country‑specific updates for cell and gene therapies.

A Regional Platform for Collaboration

ACTO provides an in‑person forum for exchanging clinical experience, regulatory perspectives, and manufacturing best practices. Sessions will include keynote lectures, panel discussions, and poster presentations — all designed to accelerate clinical translation and promote safe, effective therapies for patients.

Why ACTO Matters for Asia

• Contextualised solutions: Diverse healthcare systems in Asia require tailored approaches; ACTO fosters shared learning.
• Regulatory progress: Dialogue between regulators and developers can streamline development pathways and patient access.
• Scientific innovation: Presentations on MSCs and exosomes highlight promising avenues for next‑generation therapeutics.

Registration and Participation

Registration and abstract submission information is available on the official ACTO website. Researchers, clinicians, and industry professionals are encouraged to register early to secure participation and presentation opportunities.